Lead Product(s) : Allogeneic Induced Hepatocyte-Like Cell
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : bbHEP01 is a encapsulated allogeneic txHepatocytes for the treatment of acute liver failure, expected to enter clinical development in 2025 and generate initial clinical data in 2026.
Product Name : bbHEP01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 11, 2023
Lead Product(s) : Allogeneic Induced Hepatocyte-Like Cell
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : Khosla Ventures
Deal Size : $30.0 million
Deal Type : Series A Financing
Details : Proceeds will support the development of first candidates for IND-enabling studies, as well as expand discovery and RNA chemistry capabilities to address a wider set of serious liver-related diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 10, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : Khosla Ventures
Deal Size : $30.0 million
Deal Type : Series A Financing
Lead Product(s) : HMGB1
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : 180 Life Sciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Together with the University of Oxford, the Company plans to proceed with scaling up and Good Manufacturing Practice (GMP) production of HMGB1, as well as safety and toxicity testing in preparation for a planned Investigational New Drug (IND) application...
Product Name : HMGB1
Product Type : Peptide
Upfront Cash : Undisclosed
December 15, 2021
Lead Product(s) : HMGB1
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : 180 Life Sciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : Khosla Ventures
Deal Size : $9.6 million
Deal Type : Financing
Ochre Bio Closes $9.6M Seed Financing Led by Khosla Ventures
Details : Funding will be used to develop RNA therapies for transplant and chronic liver diseases. Ochre Bio has built a deep phenotyping platform to identify novel liver targets, validated directly in discarded human livers kept alive on machines.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
June 16, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : Khosla Ventures
Deal Size : $9.6 million
Deal Type : Financing